Proxy Votes Now

Home › Funds › BlackRock › iShares Biotechnology ETF

iShares Biotechnology ETF (IBB) proxy voting record 2025-2026

Fund family: BlackRock · Filed by iSHARES TRUST (CIK 1100663) · SEC series S000004350

Ticker: IBB (C000012080)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,712 with, 10 against, 31 abstentions (not counted as with management); 11 items carried no recommendation; 1 split votes are in neither count. Shareholder proposals: 0 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with BlackRock as a whole

The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsBlackRockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.4%1,66393.6%1,355,861
Backed environmental and social shareholder proposals at US companiesn/a15.5%6,306

Where this fund voted differently from most BlackRock funds

Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most BlackRock funds on 3 items (0.2% of the 1,425 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost BlackRock fundsMgmtResult
BIONTECH SE2026-05-15Elections to the Supervisory Board: Prof. Dr. Iris Loew-FriedrichAgainstFOR — 6 of 8 BlackRock fundsAgainst—
BIONTECH SE2026-05-15Elections to the Supervisory Board: Prof. Dr. Rudolf StaudiglAgainstFOR — 6 of 8 BlackRock fundsAgainst—
ZAI LAB LTD2026-06-17THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.ForAGAINST — 2 of 3 BlackRock fundsFor—

Download all 3 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 79.3% of this fund’s 1,753 such votes could be given a sector; the other 363 (20.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care1,31760.5%
Industrials6300.0%
Technology1000.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections9870
Audit-related2510
Say-on-Pay2350
Compensation1254
Corporate Governance893
Capital Structure800
Extraordinary Transactions130
Shareholder Rights and Defenses92
Other Social Issues31

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
GILEAD SCIENCES, INC.April 30, 2026$918M153
AMGEN INC.May 19, 2026$911M151
VERTEX PHARMACEUTICALS INCORPORATEDMay 13, 2026$829M151
REGENERON PHARMACEUTICALS, INC.June 12, 2026$725M70
MODERNA, INC.November 12, 2025$431M20
MODERNA, INC.May 6, 2026$298M50
NATERA, INC.June 11, 2026$284M80
BIOGEN INC.June 9, 2026$273M120

Notable votes against management

MeetingCompanyProposalFundMgmt
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 19, 2026AMGEN INC.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
May 13, 2026VERTEX PHARMACEUTICALS INCORPORATEDShareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
May 15, 2026MEDPACE HOLDINGS, INC.Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposalAgainstFor
June 25, 2026CELLECTIS S.A.delegation of authority to be granted to the Board of Directors to proceed with an increase in the_x000D_ share capital, the subscription of which would be reserved for the members of a company savings_x000D_ plan established pursuant to Articles L. 3332-1 et seq. of the Labor Code.ForAgainst
November 27, 2025IMMUTEP LTDApproval of Grant of Performance Rights to Mr Pete MeyersForAgainst
November 27, 2025IMMUTEP LTDApproval of Grant of Performance Rights to Dr Russell HowardForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

1,792 ballot items at 254 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, iShares Biotechnology ETF (IBB) voted at 254 shareholder meetings of 245 companies, on 1,792 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 10 times. Its most frequent area of disagreement was compensation (4 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than BlackRock's funds as a whole (92.4% against 93.6%). It voted differently from most BlackRock funds on 3 items. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.